Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative Online education and training Order products online Reimbursement resources Return a product Customer support

Call customer care

1 (888) 272-1001

SYNERGY MEGATRON™ Indications, Safety and Warnings

Return to product detail page

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Instructions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

INDICATIONS FOR USE 

The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries ≥3.50 mm to ≤5.00 mm in diameter in lesions ≤28 mm in length.

CONTRAINDICATIONS 

Use of the SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is contraindicated in patients with known hypersensitivity to:

  • 316L stainless steel, platinum, chromium, iron, nickel or molybdenum
  • Everolimus or structurally-related compounds
  • The polymer or their individual components (see Section 2.4.2 Polymer Carrier)

Coronary Artery Stenting is contraindicated for use in:

  • Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device.
  • Patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy (see Section 6.2, Pre- and Post-Procedure Antiplatelet Regimen for more information).

WARNINGS 

  • To maintain sterility, the inner package should not be opened or damaged prior to use.
  • The use of this product carries the risks associated with coronary artery stenting, including stent thrombosis, vascular complications, and/or bleeding events.
  • This product should not be used in patients who are not likely to comply with recommended antiplatelet therapy.

GENERAL PRECAUTIONS

  • Prior to angioplasty, carefully examine all equipment to be used during the procedure including the dilatation catheter to verify proper function.
  • Careful consideration should be given to the risks and benefits of use in patients with history of severe reaction to contrast agents.
  • Stent thrombosis is a rare event and is frequently associated with myocardial infarction (MI) or death. In the clinical trials analyzed to date, differences in the incidence of stent thrombosis have not been associated with an increased risk of cardiac death, MI, or all-cause mortality.
  • When drug eluting stents are used outside the specified Indications for Use, patient outcomes may differ from the results observed during the EVOLVE clinical trials.
  • Compared to use within the specified Indications for Use, the use of drug eluting stents in patients and lesions outside of the labeled indications may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI or death. When treating such patients, physicians should be aware of this increased risk and consider available data and the limitations of such data.
  • Used devices may pose a biohazard risk and must be handled and disposed of properly.

SYNERGY MEGATRON leverages the clinical data from the EVOLVE Clinical Trial Program. Therefore, the statements below regarding SYNERGY™ also apply to SYNERGY MEGATRON. 

Pre- and Post-Procedure Antiplatelet Regimen 

The optimal duration of antiplatelet therapy, specifically P2Y12 inhibitor therapy is unknown and DES thrombosis may still occur despite continuation of therapy beyond current professional society guidelines.

Oral Antiplatelet Therapy

Continuation of combination treatment with aspirin and a P2Y12 inhibitor after PCI appears to reduce major adverse cardiac events. On the basis of randomized clinical trials, the 2016 ACC/AHA guidelines recommend aspirin 81 mg daily be given indefinitely after PCI. In patients who are not at a high risk of bleeding, a P2Y12 inhibitor should be given daily for at least 6 months in stable ischemic heart disease patients and for at least 12 months in acute coronary syndrome (ACS) patients. Full guidelines are provided at the following website: http://www.onlinejacc.org It is very important that the patient is compliant with the post-procedural antiplatelet recommendations. Premature discontinuation of prescribed antiplatelet medication could result in a higher risk of thrombosis, MI or death. Prior to PCI, if asurgical or dental procedure is anticipated that requires early discontinuation of antiplatelet therapy, the interventional cardiologist and patient should carefully consider whether a DES and its associated recommended antiplatelet therapy is the appropriate PCI choice.

Pediatric Use 

The safety and effectiveness of the SYNERGY Stent in pediatric patients have not been established.

Lesion/Vessel Characteristics 

The safety and effectiveness of the SYNERGY MEGATRON Stent have not been established in the cerebral, carotid, orperipheral vasculature or in the following patient populations:

  • Patients with vessel thrombus at the lesion site.
  • Patients with coronary artery reference vessel diameters <3.50 or >5.00 mm.
  • Patients with coronary artery lesions longer than 28mm or requiring more than one SYNERGY Stent.
  • Patients with lesions located in saphenous vein grafts, in the left main coronary artery, ostial location, or complex bifurcation (e.g. bifurcation lesion requiring treatment with more than one stent).
  • Patients with diffuse disease or reduced blood flow distal to the identified lesions.
  • Patients with a recent acute ST elevation myocardial infarction where there is evidence of thrombus or poor flow.
  • Patients with in-stent restenosis.
  • Patients with a chronic total occlusion.
  • Patients with 3 vessel disease.
Magnetic Resonance Imaging (MRI) Safety Information:
 
Non-clinical testing has demonstrated that the SYNERGY MEGATRON Stent is MR Conditional for single and overlapped conditions up to 66 mm in 1.5T and 3.0T MR systems. A patient with this device can be safely scanned in a Magnetic Resonance system meeting the following conditions. Failure to follow these conditions may result in injury to the patient. If information about a specific parameter is not included, there are no conditions associated with that parameter.
  • Static magnetic field of 3.0 Tesla and 1.5 Tesla only
  • Maximum spatial gradient magnetic field of 2000 gauss/cm (20.0 T/m) for 1.5T systems and 1060 gauss/cm (10.6 T/m)for 3.0T systems
  • Maximum Magnetic Resonance system reported, whole body averaged specific absorption rate (SAR) of ≤2 W/kg(Normal Operating Mode)
  • Scanner Type: Horizonal, Cylindrical bore
  • RF Excitation: CP (Circular Polarization) 90
  • RF Transmit/ Receive Coil Type: Integrated Whole-Body Transmit/Receive Coil
  • Scan Duration: Up to 15 minutes of continuous RF (a sequence or back-to-back series/scan without breaks), followed by 5 minutes of cooling.

Under the scan conditions defined above, the SYNERGY MEGATRON Stent is expected to produce a maximum temperature rise of 5.7oC after 15 minutes of continuous scanning. In non-clinical testing, the image artifact caused by the device extends approximately 10 mm from the SYNERGY MEGATRON stent when imaged with a gradient echo pulse sequence and a 3 T MRI system as specified in ASTM F2119-01. MR Image quality may be compromised if the area of interest is within the lumen or relatively near the stent. Therefore, it maybe necessary to optimize MR imaging parameters for the presence of the stent. The artifact does obscure the device lumen. Image artifact was minimized using the spin echo sequence vs. gradient echo.

 

POTENTIAL ADVERSE EVENTS
 
Potential adverse events (in alphabetical order) which may be associated with the use of a coronary stent in native coronary arteries include but are not limited to:
  • Allergic or adverse reaction (including medications, anesthesia, contrast, or device materials)
  • Angina
  • Arrhythmias, including ventricular fibrillation, ventricular tachycardia and heart block
  • Bleeding including hemorrhage or hematoma (possibly requiring transfusion or additional intervention)
  • Cardiac failure leading to low cardiac output (cardiogenic shock) or pulmonary edema
  • Death
  • Emboli (including air, tissue, thrombus or device materials)
  • Heart failure
  • Hypotension/hypertension
  • Infection, local or systemic
  • Myocardial infarction
  • Pain or inflammation
  • Pericarditis, pericardial effusion or tamponade
  • Radiation injury
  • Renal insufficiency or failure
  • Respiratory insufficiency or failure
  • Restenosis or late acquired malapposition of treated segment
  • Stent placement issues including geographic miss, malapposition, migration, or embolization
  • Stent thrombosis/vessel occlusion
  • Stroke/cerebrovascular accident/transient ischemic attack
  • Vessel injury (including access-site) such as spasm, lymphatic problems, pseudoaneurysm, arteriovenous fistula,trauma, dissection; occlusion, perforation, and rupture.
 
Zortress, the oral formulation of everolimus developed by Novartis Pharmaceuticals Corporation, has been evaluated in clinical trials and is approved in the United States for the prevention of organ rejection in adult kidney transplant recipients at the dose of1.5 mg/day. Outside the U.S., Zortress is sold under the brand name, Certican, in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor™ for patients with advanced renal cell carcinoma (cancer), after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The following list includes the known risks of everolimus at the oral doses listed above. The amount of drug that circulates in the bloodstream following implantation ofa SYNERGY MEGATRON™ Stent is several folds lower than that obtained with oral doses (1.5 mg to 20 mg/day, see Section7.2, Pharmacokinetics). Adverse events associated with daily oral administration of everolimus (or potential adverse events not captured above, that may be unique to the everolimus drug coating) can be found in the labeling for finished pharmaceuticals containing everolimus, such as Afinitor or Zortress.
Top